MDAI ROSECLIFF ACQUISITION CORP I

Spectral AI to Participate in the Northland Capital Markets Virtual Growth Conference

Spectral AI to Participate in the Northland Capital Markets Virtual Growth Conference

DALLAS, June 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will participate in the Northland Capital Markets Virtual Growth Conference on Tuesday, June 25, 2024.

Spectral AI CEO Peter M. Carlson and Chief Financial Officer Vincent S. Capone will host virtual one-on-one meetings with institutional investors throughout the day.

Spectral AI’s DeepView™ System utilizes proprietary multispectral imaging, trained and tested against a proprietary database of more than 340 billion clinically validated data points, to distinguish between healthy and damaged tissue to deliver a rapid and objective assessment as to whether a burn wound will heal naturally or requires surgical intervention.

In February 2024, the Company received UK Conformity Assessed (UKCA) authorization for the DeepView™ System for burn indication and expects to generate its first commercial product revenue later this year. Spectral AI is on track to file additional UK and US regulatory submissions in 2024 and 2025 for the approval of the DeepView™ System and expects to expand its commercial revenue platforms over the next two years.

For more information on the Northland Capital Markets Virtual Growth Conference, or to schedule a one-on-one meeting with Spectral AI management, please contact your Northland representative or The Equity Group.

About Spectral AI 

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView™ System. The DeepView™ System is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to change the current standard of care, the DeepView™ System is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about the DeepView™ System, visit . 

Forward-Looking Statements 

Certain statements made in this release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. 

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. 

Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. 

Investors: 

The Equity Group 

Devin Sullivan 

Managing Director 

 

Conor Rodriguez 

Analyst 



EN
17/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ROSECLIFF ACQUISITION CORP I

 PRESS RELEASE

Spectral AI Announces Submission to FDA of its DeepView® System

Spectral AI Announces Submission to FDA of its DeepView® System DALLAS, June 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and artificial intelligence (“AI”) algorithms to predict burn healing potential, today announced the submission of its De Novo 510k marketing clearance application to the FDA for the DeepView System, intended for use in burn care settings, inclu...

 PRESS RELEASE

DeepView® System highlighted at the annual British Burn Association co...

DeepView® System highlighted at the annual British Burn Association conference DALLAS, June 10, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the annual British Burn Association (BBA) conference, held from June 4th – 6th in Brighton, UK. The Company was featured in multiple presentations, highlighting its contributions to advancing burn care across the globe. Key Presentat...

 PRESS RELEASE

Spectral AI Announces Appointment of Stanley Micek as Chief Operating ...

Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company’s Chief Operating Officer (“COO”). Micek’s promotion reflects his role change from Interim COO of the Company since May, 2024 “Stan has demonstrated exceptional leadership, operational insight, and a deep unde...

 PRESS RELEASE

Spectral AI Announces Voting Results from 2025 Annual Meeting of Stock...

Spectral AI Announces Voting Results from 2025 Annual Meeting of Stockholders DALLAS, May 29, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced results from its 2025 Annual Meeting of Stockholders held earlier today. A total of 15,551,068 shares representing 60.8% of the Company’s total shares outstanding were represented at the meeting, either in person or by proxy. Both of the proposals set forth by the...

 PRESS RELEASE

DeepView® System Achieves 95.3% Accuracy Evaluation as Published in Bu...

DeepView® System Achieves 95.3% Accuracy Evaluation as Published in Burns Journal DALLAS, May 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today announced that the Company’s DeepView System has been featured in the journal Burns as part of a clinical study in which it achieved a 95.3% overall accuracy assessment as compared to traditional subjective assessments. Chris Lewis, a lead author of the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch